Piper Sandler Reiterates Overweight on Dyne Therapeutics (DYN) as 'DYNE-251 Continues to DELIVER'
Tweet Send to a Friend
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $48.00 price target on Dyne Therapeutics (NASDAQ: DYN).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
